The FDA is raising repeat safety and efficacy questions ahead of an advisory committee meeting on Thursday for Lexicon Pharmaceuticals' SGLT2 inhibitor sotagliflozin, which the agency rejected in 2019 for type 1 diabetes.
The original ...
↧
